Résultats de la recherche - 65 results

Clinical performance of the novel full-genotyping OncoPredict HPV Quantitative Typing assay using the VALGENT framework.

Cuschieri, Kate; M. Arbyn Source: Int J Cancer, Volume 154, Issue 3 (2024) Keywords: Adult Early Detection of Cancer Female Genotype Genotyping Techniques Humans middle aged Papillomaviridae Papillomavirus ...

Human papillomavirus negative high grade cervical lesions and cancers: Suggested guidance for HPV testing quality assurance

Publication Type: Peer reviewed scientific article Authors: Prétet, Jean Luc; Arroyo Mühr, Laila Sara; Cuschieri, Kate; Fellner, María Dolores; Correa, Rita Mariel; Picconi, María Alejandra; Garland, Suzanne M.; Murray, Gerald L.; Molano, Monica; Michael ...

Can REALQUALITY RQ-HPV screen be considered as a clinically validated HPV test for use in cervical cancer screening?

Detection of Cancer Female Humans Mass Screening Papillomaviridae Papillomavirus Infections Uterine Cervical Dysplasia Uterine Cervical Neoplasms Vaginal Smears Abstract: “Can REALQUALITY RQ- HPV screen be ...

HPV-based Cervical Cancer Screening on Self-samples in the Netherlands: Challenges to Reach Women and Test Performance Questions.

E Source: Cancer Epidemiol Biomarkers Prev, Volume 32, Issue 2 (2023) Keywords: Early Detection of Cancer Female Humans Mass Screening Netherlands Papillomaviridae Papillomavirus Infections specimen handling ...

Do genomic passports leave us more vulnerable or less vulnerable? Perspectives from an online citizen engagement

cancer Kankercentrum Cancer centre Manuscript versions:  DOI:  https://sciensano.be/en/10.1057/s41599-023-01580-7 File:  Version:  Published Full text access:  Public Access Full text language:  English ...

Evaluation of the clinical performance of OncoPredict HPV® SCR assay within the VALGENT‐2 framework

Kate; M. Arbyn Source: Journal of Medical Virology, Volume 95, Issue 1 (2023) Keywords: cervical cancer HPV genotyping human papillomavirus OncoPredict HPV® test validation. VALGENT Abstract: Human ...

Humoral and cellular immune responses against SARS-CoV-2 after third dose BNT162b2 following double-dose vaccination with BNT162b2 versus ChAdOx1 in cancer patients.

Marc; Peter A van Dam Source: Clin Cancer Res (2022) Abstract: PURPOSE: Cancer patients display reduced humoral responses after double-dose COVID-19 vaccination while their cellular response is more ...

Accuracy of high-risk HPV DNA PCR, p16(INK4a) immunohistochemistry or the combination of both to diagnose HPV-driven oropharyngeal cancer

cancers (OPC), is increasing in high-resource countries. Patients with HPV-induced cancer respond better to treatment and consequently have lower case-fatality rates than patients with HPV-unrelated OPC. ...

Predictive model for BNT162b2 vaccine response in cancer patients based on blood cytokines and growth factors.

cancer, especially hematological cancer, are at increased risk for breakthrough COVID-19 infection. So far, a predictive biomarker that can assess compromised vaccine-induced anti- SARS-CoV-2 immunity in ...

Healthy Data, an online citizen consultation about health data reuse – intermediate report

Service:  Centre du cancer Kankercentrum Cancer centre Manuscript versions:  File:  Version:  Published Full text access:  Public Access Full text language:  English Category:  Scientific reports, ...

QR code

QR code for this page URL